Microsoft’s Mustafa Suleyman says its AI outperforms doctors on hard cases as he chases ‘medical superintelligence’
Microsoft’s new AI diagnostic system beat generalist doctors on hard cases, according to a study in Science. But most of the improvement seems to come from the AI models underneath, not from Microsoft’s system itself.
Covered in this story
Analyst targets on Microsoft
- StoneX: $529 → $600 by Oct 2027 · Buy via GuruFocus
- UBS: $529 → $675 by Oct 2027 · Buy via TheStreet
- Melius Research: $529 → $665 by Oct 2027 · Buy via TheStreet
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MSFT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Microsoft →Dalsna Finance is currently tracking 61 stories mentioning Microsoft, the earliest published 29 Jul 2026.
Summary aggregated from TechCrunch's public RSS feed. The full reporting belongs to TechCrunch — please read it on their site.